Jul 30, 2026 11:00AM
Jul 30, 2026 11:00AM
Jul 6, 2026 09:11AM
Jul 6, 2026 09:10AM
Jun 25, 2026 09:10AM
Jun 23, 2026 09:25AM
Jun 17, 2026 09:25AM GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
Jun 9, 2026 09:25AM
Jun 9, 2026 09:25AM
Jun 3, 2026 09:25AM
May 19, 2026 09:15AM
May 7, 2026 09:25AM
May 5, 2026 09:11AM
May 5, 2026 09:10AM Lexaria Updates Progress on Human Study #7
May 1, 2026 09:25AM
Apr 29, 2026 09:10AM
Apr 29, 2026 09:10AM
Apr 23, 2026 09:05AM
Apr 21, 2026 09:10AM
Apr 15, 2026 09:10AM
Apr 7, 2026 09:10AM Lexaria notes FDA approval of Eli Lilly's oral weight-loss drug Foundayo
Apr 7, 2026 09:10AM
Apr 1, 2026 09:20AM
Apr 1, 2026 09:20AM
Mar 26, 2026 09:20AM
Mar 26, 2026 09:20AM
Mar 24, 2026 09:15AM
Mar 24, 2026 09:15AM Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
Mar 4, 2026 09:25AM
Mar 4, 2026 09:25AM
Feb 5, 2026 09:15AM
Jan 22, 2026 09:22AM
Jan 22, 2026 09:20AM
Jan 12, 2026 09:10AM
Jan 12, 2026 09:10AM Lexaria Releases Annual Letter from the CEO
Dec 30, 2025 09:20AM
Dec 30, 2025 09:20AM
Dec 23, 2025 09:29AM
Dec 23, 2025 09:29AM
Dec 16, 2025 04:00PM
Dec 16, 2025 04:00PM
Dec 15, 2025 08:01AM Lexaria Bioscience raises $3.5 million in registered direct offering
Dec 15, 2025 08:00AM
Nov 12, 2025 09:11AM
Nov 12, 2025 09:10AM
Oct 9, 2025 09:20AM
Oct 9, 2025 09:20AM
Sep 29, 2025 04:30PM
Sep 29, 2025 04:30PM Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Sep 26, 2025 08:00AM

327,783 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All